4.14
Schlusskurs vom Vortag:
$4.16
Offen:
$4.1
24-Stunden-Volumen:
2.70M
Relative Volume:
0.64
Marktkapitalisierung:
$408.12M
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-31.22
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
-5.69%
1M Leistung:
-1.19%
6M Leistung:
-7.80%
1J Leistung:
-40.09%
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
GDRX
Goodrx Holdings Inc
|
4.14 | 1.45B | 775.09M | -58.68M | 64.06M | -0.1326 |
![]()
VEEV
Veeva Systems Inc
|
287.65 | 46.89B | 2.97B | 809.93M | 1.33B | 4.8743 |
![]()
TEM
Tempus Ai Inc
|
89.87 | 16.41B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
67.03 | 12.64B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
94.04 | 8.03B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
36.62 | 6.90B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
2024-12-04 | Eingeleitet | Mizuho | Neutral |
2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
2022-12-01 | Eingeleitet | Citigroup | Buy |
2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2022-09-07 | Eingeleitet | Truist | Hold |
2022-08-12 | Eingeleitet | DA Davidson | Neutral |
2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
2022-06-06 | Fortgesetzt | BofA Securities | Buy |
2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
2022-04-07 | Eingeleitet | Guggenheim | Buy |
2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2022-03-01 | Bestätigt | Barclays | Overweight |
2022-03-01 | Bestätigt | BofA Securities | Neutral |
2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
2022-03-01 | Bestätigt | Evercore ISI | Outperform |
2022-03-01 | Bestätigt | Goldman | Buy |
2022-03-01 | Bestätigt | JP Morgan | Underweight |
2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
2022-03-01 | Bestätigt | SVB Leerink | Outperform |
2022-01-07 | Eingeleitet | Goldman | Buy |
2021-12-21 | Eingeleitet | Stephens | Overweight |
2021-12-02 | Eingeleitet | Jefferies | Buy |
2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
2021-01-25 | Eingeleitet | Guggenheim | Buy |
2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-10-19 | Eingeleitet | Barclays | Equal Weight |
2020-10-19 | Eingeleitet | BofA Securities | Neutral |
2020-10-19 | Eingeleitet | Citigroup | Buy |
2020-10-19 | Eingeleitet | Cowen | Outperform |
2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
2020-10-19 | Eingeleitet | Goldman | Neutral |
2020-10-19 | Eingeleitet | JP Morgan | Neutral |
2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
How to use a screener to detect GoodRx Holdings Inc. breakoutsForecast Cut & Expert Curated Trade Ideas - newser.com
Real time social sentiment graph for GoodRx Holdings Inc.Quarterly Profit Report & Technical Entry and Exit Tips - newser.com
How analysts rate GoodRx Holdings Inc. stock todayWeekly Investment Recap & Weekly High Conviction Ideas - newser.com
Institutional scanner results for GoodRx Holdings Inc.Weekly Market Report & Free High Return Stock Watch Alerts - newser.com
How sentiment analysis helps forecast GoodRx Holdings Inc.CEO Change & Accurate Intraday Trade Tips - newser.com
What Fibonacci levels say about GoodRx Holdings Inc. rebound2025 Major Catalysts & High Conviction Trade Alerts - newser.com
Will GoodRx Holdings Inc. stock recover after recent dropTrade Volume Summary & Detailed Earnings Play Strategies - newser.com
GoodRx (NASDAQ:GDRX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
GoodRx (NASDAQ:GDRX) Shares Up 10.5%Here's Why - MarketBeat
GoodRx Holdings Inc Stock Analysis and ForecastPrice-to-Book Ratio Updates & Free High Velocity Capital Growth - earlytimes.in
Tandem Diabetes, agilon health, GoodRx, Neogen, and Fortrea Stocks Trade Down, What You Need To Know - The Globe and Mail
GoodRx: Novo Deal And TrumpRx Talks Point To EBITDA/FCF Upside (NASDAQ:GDRX) - Seeking Alpha
Price action breakdown for GoodRx Holdings Inc.Quarterly Earnings Summary & Stepwise Trade Execution Plans - newser.com
What technical models suggest about GoodRx Holdings Inc.’s comebackPortfolio Update Report & Advanced Swing Trade Entry Alerts - newser.com
GoodRx’s Stock Soars: What’s Behind the Uptick? - timothysykes.com
BofA Securities maintains Underperform rating on GoodRx stock amid TrumpRx uncertainty - Investing.com
GoodRx (GDRX) Faces Uncertain Impact from Potential TrumpRx Coll - GuruFocus
Trump Administration Engages Pharmacies, GoodRx For TrumpRx LaunchGoodRx Holdings (NASDAQ:GDRX) - Benzinga
BofA on GoodRx Holdings Inc. (GDRX): 'We don’t have a strong view at this time on the potential upside/downside from TrumpRx' - StreetInsider
GoodRx (GDRX) Shares Surge as Talks with White House Progress - GuruFocus
GoodRx: Game-Changer Partnerships on the Horizon? - StocksToTrade
GoodRx stock surges as company discusses TrumpRx role with administration - Investing.com Nigeria
GoodRx stock spikes on plans to join TrumpRx (GDRX:NASDAQ) - Seeking Alpha
Candlestick signals on GoodRx Holdings Inc. stock todayBull Run & Growth-Oriented Investment Plans - newser.com
What machine learning models say about GoodRx Holdings Inc.Portfolio Value Summary & Accurate Buy Signal Alerts - newser.com
GoodRx (NASDAQ:GDRX) Earns Hold (C-) Rating from Weiss Ratings - MarketBeat
GoodRx Holdings, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape - Markets Mojo
GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call - The Joplin Globe
News - FinancialContent
GoodRx (GDRX) Faces Industry Changes Amid BlinkRx Developments - GuruFocus
Q2 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks - The Globe and Mail
GoodRx (GDRX) Cuts Cost of Repatha to Boost Patient Savings - GuruFocus
GoodRx expands affordable access to Repatha® with nearly 60% savings - MarketScreener
Can trapped investors hope for a rebound in GoodRx Holdings Inc.Market Growth Review & Capital Protection Trade Alerts - newser.com
$239 cash price for Repatha — GoodRx expands access with nearly 60% savings at 70,000+ pharmacies - Stock Titan
Can you recover from losses in GoodRx Holdings Inc.Portfolio Performance Report & Long-Term Capital Growth Strategies - newser.com
Is GoodRx Holdings Inc. stock entering bullish territoryShare Buyback & Safe Entry Point Alerts - newser.com
GoodRx Holdings Inc. (GDRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why GoodRx (GDRX) Stock Is Up Today - The Globe and Mail
GoodRx (GDRX): Evaluating the Stock’s Valuation After Recent Share Price Volatility - Yahoo Finance
How to recover losses in GoodRx Holdings Inc. stockWeekly Stock Summary & Entry Point Confirmation Signals - newser.com
What’s the recovery path for long term holders of GoodRx Holdings Inc.Quarterly Portfolio Review & Reliable Intraday Trade Plans - newser.com
Is GoodRx Holdings Inc. stock a buy for dividend growthPrice Action & Weekly Market Pulse Alerts - newser.com
GoodRx Target of Unusually High Options Trading (NASDAQ:GDRX) - MarketBeat
Should You Think About Buying GoodRx Holdings, Inc. (NASDAQ:GDRX) Now? - simplywall.st
What analysts say about GoodRx Holdings Inc stockStock Buyback Announcements & Low Risk Capital Appreciation - earlytimes.in
GoodRx stock surges on potential TrumpRx partnership and Kroger expansion - Investing.com
GoodRx (GDRX) Stock Climbs as Citi Reaffirms Buy Rating - GuruFocus
GoodRx (GDRX) Shares Surge 19% After CEO's Comments - GuruFocus
GoodRx (GDRX) Shares Rise on Potential Inclusion in TrumpRx Init - GuruFocus
GoodRx gains with late session surge on CEO remarks; closes up 19% - Seeking Alpha
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):